PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 297 filers reported holding PACIRA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 9.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $1,892,466 | -1.8% | 47,229 | +0.0% | 0.02% | -6.2% |
Q1 2023 | $1,927,252 | +1.9% | 47,225 | -3.6% | 0.02% | -5.9% |
Q4 2022 | $1,890,693 | -62.3% | 48,969 | -25.5% | 0.02% | -43.3% |
Q1 2022 | $5,020,000 | +29.4% | 65,765 | +2.0% | 0.03% | +50.0% |
Q4 2021 | $3,879,000 | -24.6% | 64,460 | -29.8% | 0.02% | -35.5% |
Q3 2021 | $5,145,000 | -10.1% | 91,868 | -2.6% | 0.03% | -8.8% |
Q2 2021 | $5,725,000 | +171.7% | 94,350 | +213.8% | 0.03% | +142.9% |
Q1 2021 | $2,107,000 | -10.4% | 30,066 | -23.5% | 0.01% | -6.7% |
Q4 2020 | $2,352,000 | -8.5% | 39,309 | -24.8% | 0.02% | -11.8% |
Q3 2018 | $2,570,000 | +30.9% | 52,296 | -14.6% | 0.02% | +30.8% |
Q2 2018 | $1,964,000 | -8.3% | 61,245 | -10.9% | 0.01% | +160.0% |
Q1 2018 | $2,141,000 | -17.1% | 68,706 | +21.4% | 0.01% | -16.7% |
Q4 2017 | $2,584,000 | -13.1% | 56,594 | -28.5% | 0.01% | -14.3% |
Q3 2017 | $2,972,000 | -5.4% | 79,122 | +20.1% | 0.01% | -12.5% |
Q2 2017 | $3,143,000 | +24.6% | 65,867 | +19.1% | 0.01% | +14.3% |
Q1 2017 | $2,523,000 | +13.9% | 55,310 | -19.4% | 0.01% | +16.7% |
Q4 2016 | $2,215,000 | -5.9% | 68,588 | -0.3% | 0.01% | -14.3% |
Q3 2016 | $2,355,000 | -1.6% | 68,827 | -3.0% | 0.01% | -12.5% |
Q2 2016 | $2,394,000 | -30.7% | 70,968 | +8.9% | 0.01% | -27.3% |
Q1 2016 | $3,453,000 | +5.1% | 65,178 | +52.2% | 0.01% | +10.0% |
Q4 2015 | $3,287,000 | +769.6% | 42,810 | +365.1% | 0.01% | +900.0% |
Q3 2015 | $378,000 | -89.3% | 9,204 | -81.6% | 0.00% | -88.9% |
Q2 2015 | $3,532,000 | -5.7% | 49,951 | +18.6% | 0.01% | 0.0% |
Q1 2015 | $3,744,000 | +26.1% | 42,132 | +25.8% | 0.01% | +28.6% |
Q4 2014 | $2,969,000 | +132.9% | 33,490 | +154.7% | 0.01% | +133.3% |
Q3 2014 | $1,275,000 | +25.0% | 13,151 | +18.4% | 0.00% | 0.0% |
Q2 2014 | $1,020,000 | +64.3% | 11,105 | -48.1% | 0.00% | 0.0% |
Q2 2013 | $621,000 | – | 21,406 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |